Receptor-Interacting Protein Kinase 1 (RIPK1) as a Potential Therapeutic Target: An Overview of Its Possible Role in the Pathogenesis of Alzheimer's Disease

Author(s): Hong Hao Chan, Rhun Yian Koh*, Chooi Ling Lim, Chee Onn Leong.

Journal Name: Current Alzheimer Research

Volume 16 , Issue 10 , 2019

Become EABM
Become Reviewer


Alzheimer’s Disease (AD) is an age-dependent neurodegenerative disorder, the most common type of dementia that is clinically characterized by the presence of beta-amyloid (Aβ) extracellularly and intraneuronal tau protein tangles that eventually leads to the onset of memory and cognition impairment, development of psychiatric symptoms and behavioral disorders that affect basic daily activities. Current treatment approved by the U.S Food and Drug Administration (FDA) for AD is mainly focused on the symptoms but not on the pathogenesis of the disease. Recently, receptor-interacting protein kinase 1 (RIPK1) has been identified as a key component in the pathogenesis of AD through necroptosis. Furthermore, genetic and pharmacological suppression of RIPK1 has been shown to revert the phenotype of AD and its mediating pathway is yet to be deciphered. This review is aimed to provide an overview of the pathogenesis and current treatment of AD with the involvement of autophagy as well as providing a novel insight into RIPK1 in reverting the progression of AD, probably through an autophagy machinery.

Keywords: Alzheimer's disease, neurodegenerative disorder, dementia, beta amyloid, receptor interacting protein kinase 1, autophagy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Page: [907 - 918]
Pages: 12
DOI: 10.2174/1567205016666191023102422
Price: $58

Article Metrics

PDF: 3